ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Pfizer, Hoffmann-La Roche and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Pfizer×Hoffmann-La Roche×Merck×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PfizerHoffmann-La RocheMerck
studies on the registry4,0732,7442,455
open to participants now147114146
phase 3 studies under way9995112
reach primary completion within a year927659
programswith a study of their own in two years91+9 named only80+25 named only84

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePfizerHoffmann-La RocheMerck
Phase 1

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 2

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
23%
Phase 3

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%
Approved, new studies

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 7

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 60 in all. A program counts in each condition its studies name most.

ConditionPfizerHoffmann-La RocheMerck
Carcinoma, Non-Small-Cell Lungall three · compare here

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsall three · compare here

Pfizer in Neoplasms: 2 programs

  1. polfurmetinibphase 1
  2. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Breast Neoplasmsall three · compare here

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Obesityall three · compare here

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Hoffmann-La Roche in Obesity: 5 programs

  1. enicepatidephase 3
  2. petrelintidephase 3
  3. emugrobartphase 3
  4. tifeglipronphase 2
  5. HM17321no phase

Their studies: Hoffmann-La Roche’s studies of Obesity in search

Merck in Obesity: 3 programs

  1. efinopegdutidephase 2
  2. TERN-601phase 2
  3. Metforminapproved, new study

Their studies: Merck’s studies of Obesity in search

Renal Insufficiencyall three · compare here

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

Hoffmann-La Roche in Renal Insufficiency: 3 programs

  1. petrelintidephase 3
  2. tifeglipronphase 2
  3. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Renal Insufficiency in search

Merck in Renal Insufficiency: 7 programs

  1. calderasibphase 3
  2. nemtabrutinibphase 3
  3. alimatravirphase 3
  4. enlicitide chloridephase 3
  5. doravirinephase 3

and 2 more — sign in to see them all

Their studies: Merck’s studies of Renal Insufficiency in search

Colorectal Neoplasmsall three · compare here

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Merck in Colorectal Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. Cetuximabphase 3

Their studies: Merck’s studies of Colorectal Neoplasms in search

Dermatitis, Atopicall three · compare here

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

Merck in Dermatitis, Atopic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Dermatitis, Atopic in search

Alzheimer Diseaseall three · compare here

Pfizer in Alzheimer Disease: 1 program

  1. PF-08161842phase 1

Their studies: Pfizer’s studies of Alzheimer Disease in search

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Diabetes Mellitus, Type 2all three · compare here

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Small Cell Lung Carcinomaall three · compare here

Pfizer in Small Cell Lung Carcinoma: 3 programs

  1. tivunatamigphase 3
  2. mevrometostatphase 3
  3. tegtociclibphase 2

Their studies: Pfizer’s studies of Small Cell Lung Carcinoma in search

Merck in Small Cell Lung Carcinoma: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. gocatamigphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Small Cell Lung Carcinoma in search

COVID-19all three · compare here

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

Hoffmann-La Roche in COVID-19: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of COVID-19 in search

Merck in COVID-19: 2 programs

  1. molnupiravirphase 3
  2. frespaciguatphase 3

Their studies: Merck’s studies of COVID-19 in search

Colitis, Ulcerativeall three · compare here

Pfizer in Colitis, Ulcerative: 2 programs

  1. etrasimodphase 3
  2. PF-07054894phase 1

Their studies: Pfizer’s studies of Colitis, Ulcerative in search

Hoffmann-La Roche in Colitis, Ulcerative: 2 programs

  1. afimkibartphase 3
  2. RO7837195phase 2

Their studies: Hoffmann-La Roche’s studies of Colitis, Ulcerative in search

Merck in Colitis, Ulcerative: 3 programs

  1. tulisokibartphase 3
  2. MK-8690phase 2
  3. MK-6194phase 2

Their studies: Merck’s studies of Colitis, Ulcerative in search

Melanomaall three · compare here

Hoffmann-La Roche in Melanoma: 1 program

  1. autogene cevumeranphase 2

Their studies: Hoffmann-La Roche’s studies of Melanoma in search

Merck in Melanoma: 3 programs

  1. intismeran autogenephase 3
  2. BCG Vaccinephase 2
  3. pembrolizumabapproved, new study

Their studies: Merck’s studies of Melanoma in search

Non-Muscle Invasive Bladder Neoplasmsall three · compare here

Hoffmann-La Roche in Non-Muscle Invasive Bladder Neoplasms: 1 program

  1. eciskafusp alfaphase 1

Their studies: Hoffmann-La Roche’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Merck in Non-Muscle Invasive Bladder Neoplasms: 2 programs

  1. intismeran autogenephase 3
  2. BCG Vaccinephase 2

Their studies: Merck’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Lupus Erythematosus, Systemicall three · compare here

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Merck in Lupus Erythematosus, Systemic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Lupus Erythematosus, Systemic in search

Multiple Myelomaall three · compare here

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Merck in Multiple Myeloma: 1 program

  1. sotaterceptapproved, new study

Their studies: Merck’s studies of Multiple Myeloma in search

Ovarian Neoplasmsall three · compare here

Pfizer in Ovarian Neoplasms: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Ovarian Neoplasms in search

Hoffmann-La Roche in Ovarian Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Ovarian Neoplasms in search

Arthritis, Rheumatoidall three · compare here

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Merck in Arthritis, Rheumatoid: 1 program

  1. MK-8690phase 2

Their studies: Merck’s studies of Arthritis, Rheumatoid in search

Asthmaall three · compare here

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

Hoffmann-La Roche in Asthma: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Asthma in search

Merck in Asthma: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Asthma in search

Influenza, Humanall three · compare here

Pfizer in Influenza, Human: 3 programs

  1. abrysvophase 3
  2. qIRVphase 1
  3. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Influenza, Human in search

Hoffmann-La Roche in Influenza, Human: 1 program

  1. baloxavirphase 3

Their studies: Hoffmann-La Roche’s studies of Influenza, Human in search

Merck in Influenza, Human: 1 program

  1. efitazanamivir alfaphase 3

Their studies: Merck’s studies of Influenza, Human in search

Prostatic Neoplasmsall three · compare here

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

Neoplasm Metastasisall three · compare here

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

Merck in Neoplasm Metastasis: 1 program

  1. MK-8294phase 1

Their studies: Merck’s studies of Neoplasm Metastasis in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

Pfizer in Pulmonary Disease, Chronic Obstructive: 1 program

  1. tilrekimigphase 3

Their studies: Pfizer’s studies of Pulmonary Disease, Chronic Obstructive in search

Hoffmann-La Roche in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. astegolimabphase 3
  2. RO7830698phase 2

Their studies: Hoffmann-La Roche’s studies of Pulmonary Disease, Chronic Obstructive in search

Merck in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Pulmonary Disease, Chronic Obstructive in search

Crohn Diseaseall three · compare here

Pfizer in Crohn Disease: 1 program

  1. etrasimodphase 3

Their studies: Pfizer’s studies of Crohn Disease in search

Hoffmann-La Roche in Crohn Disease: 1 program

  1. afimkibartphase 3

Their studies: Hoffmann-La Roche’s studies of Crohn Disease in search

Merck in Crohn Disease: 1 program

  1. tulisokibartphase 3

Their studies: Merck’s studies of Crohn Disease in search

Diabetes Mellitusall three · compare here

Pfizer in Diabetes Mellitus: 1 program

  1. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus in search

Hoffmann-La Roche in Diabetes Mellitus: 1 program

  1. enicepatidephase 3

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus in search

Merck in Diabetes Mellitus: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus in search

Endometrial Neoplasmsall three · compare here

Pfizer in Endometrial Neoplasms: 1 program

  1. tivunatamigphase 3

Their studies: Pfizer’s studies of Endometrial Neoplasms in search

Hoffmann-La Roche in Endometrial Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Endometrial Neoplasms in search

Merck in Endometrial Neoplasms: 1 program

  1. sacituzumab tirumotecanphase 3

Their studies: Merck’s studies of Endometrial Neoplasms in search

Hypertensionall three · compare here

Pfizer in Hypertension: 1 program

  1. Prazosinphase 1

Their studies: Pfizer’s studies of Hypertension in search

Hoffmann-La Roche in Hypertension: 1 program

  1. zilebesiranphase 3

Their studies: Hoffmann-La Roche’s studies of Hypertension in search

Merck in Hypertension: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Hypertension in search

Stomach Neoplasmsall three · compare here

Pfizer in Stomach Neoplasms: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

Merck in Stomach Neoplasms: 1 program

  1. pembrolizumabapproved, new study

Their studies: Merck’s studies of Stomach Neoplasms in search

Macular Edema2 of 3 · compare here–

Hoffmann-La Roche in Macular Edema: 6 programs

  1. vamikibartphase 3
  2. RO7446603phase 2
  3. RO7497372phase 1
  4. RO7823653phase 1
  5. Ranibizumabapproved, new study

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Macular Edema in search

Merck in Macular Edema: 1 program

  1. remigromigphase 3

Their studies: Merck’s studies of Macular Edema in search

Pneumococcal Infections2 of 3 · compare here

Pfizer in Pneumococcal Infections: 4 programs

  1. PG4phase 3
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3
  3. PG4 Multivalent Vaccinephase 3
  4. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Pneumococcal Infections in search

–

Merck in Pneumococcal Infections: 2 programs

  1. V118Cphase 1
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Pneumococcal Infections in search

Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here–

Hoffmann-La Roche in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. mosunetuzumabphase 3
  2. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Merck in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3
  2. nemtabrutinibphase 3
  3. zilovertamab vedotinphase 3

Their studies: Merck’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Macular Degeneration2 of 3 · compare here–

Hoffmann-La Roche in Macular Degeneration: 4 programs

  1. avacincaptad pegolphase 1
  2. pegcetacoplanphase 1
  3. Ranibizumabapproved, new study
  4. faricimabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Macular Degeneration in search

Merck in Macular Degeneration: 1 program

  1. remigromigphase 3

Their studies: Merck’s studies of Macular Degeneration in search

Esophageal Neoplasms2 of 3 · compare here

Pfizer in Esophageal Neoplasms: 2 programs

  1. PF-08046033phase 1
  2. PF-08098488phase 1

Their studies: Pfizer’s studies of Esophageal Neoplasms in search

–

Merck in Esophageal Neoplasms: 2 programs

  1. patritumab deruxtecanphase 3
  2. Rescue Medicationsphase 2

Their studies: Merck’s studies of Esophageal Neoplasms in search

Hemophilia A2 of 3 · compare here

Pfizer in Hemophilia A: 1 program

  1. marstacimabphase 3

Their studies: Pfizer’s studies of Hemophilia A in search

Hoffmann-La Roche in Hemophilia A: 3 programs

  1. zemocimigphase 3
  2. dirloctocogene samoparvovecphase 2
  3. emicizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Hemophilia A in search

–
Hepatic Insufficiency2 of 3 · compare here

Pfizer in Hepatic Insufficiency: 1 program

  1. atirmociclibphase 3

Their studies: Pfizer’s studies of Hepatic Insufficiency in search

–

Merck in Hepatic Insufficiency: 3 programs

  1. bomedemstatphase 3
  2. ulonivirinephase 3
  3. enlicitide chloridephase 3

Their studies: Merck’s studies of Hepatic Insufficiency in search

HIV Infections2 of 3 · compare here

Pfizer in HIV Infections: 1 program

  1. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of HIV Infections in search

–

Merck in HIV Infections: 3 programs

  1. islatravirphase 3
  2. doravirinephase 3
  3. MK4646phase 1

Their studies: Merck’s studies of HIV Infections in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Large B-Cell, Diffuse in search

Triple Negative Breast Neoplasms2 of 3 · compare here

Pfizer in Triple Negative Breast Neoplasms: 1 program

  1. KAT6/KAT7 Inhibitor PF-08032562phase 1

Their studies: Pfizer’s studies of Triple Negative Breast Neoplasms in search

–

Merck in Triple Negative Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. zilovertamab vedotinphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Triple Negative Breast Neoplasms in search

Carcinoma, Transitional Cell2 of 3 · compare here

Pfizer in Carcinoma, Transitional Cell: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Carcinoma, Transitional Cell in search

–
Hypertension, Pulmonary2 of 3 · compare here

Pfizer in Hypertension, Pulmonary: 1 program

  1. PF-07868489phase 2

Their studies: Pfizer’s studies of Hypertension, Pulmonary in search

–

Merck in Hypertension, Pulmonary: 2 programs

  1. frespaciguatphase 3
  2. sotaterceptapproved, new study

Their studies: Merck’s studies of Hypertension, Pulmonary in search

Lymphoma, Non-Hodgkin2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, Non-Hodgkin: 2 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Non-Hodgkin in search

Merck in Lymphoma, Non-Hodgkin: 1 program

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3

Their studies: Merck’s studies of Lymphoma, Non-Hodgkin in search

Pneumonia, Pneumococcal2 of 3 · compare here

Pfizer in Pneumonia, Pneumococcal: 2 programs

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 3
  2. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Pneumonia, Pneumococcal in search

–

Merck in Pneumonia, Pneumococcal: 1 program

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Pneumonia, Pneumococcal in search

Pulmonary Arterial Hypertension2 of 3 · compare here

Pfizer in Pulmonary Arterial Hypertension: 1 program

  1. PF-07868489phase 2

Their studies: Pfizer’s studies of Pulmonary Arterial Hypertension in search

–

Merck in Pulmonary Arterial Hypertension: 2 programs

  1. frespaciguatphase 3
  2. sotaterceptapproved, new study

Their studies: Merck’s studies of Pulmonary Arterial Hypertension in search

Respiratory Syncytial Virus Infections2 of 3 · compare here

Pfizer in Respiratory Syncytial Virus Infections: 2 programs

  1. abrysvophase 3
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3

Their studies: Pfizer’s studies of Respiratory Syncytial Virus Infections in search

–

Merck in Respiratory Syncytial Virus Infections: 1 program

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Respiratory Syncytial Virus Infections in search

Retinal Vein Occlusion2 of 3 · compare here–

Hoffmann-La Roche in Retinal Vein Occlusion: 1 program

  1. Ranibizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Retinal Vein Occlusion in search

Merck in Retinal Vein Occlusion: 2 programs

  1. MK-8748phase 3
  2. remigromigphase 3

Their studies: Merck’s studies of Retinal Vein Occlusion in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Pfizer in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpha V Beta 8 Antagonist PF-06940434phase 1

Their studies: Pfizer’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

Merck in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. Cetuximabphase 3
  2. pembrolizumabapproved, new study

Their studies: Merck’s studies of Squamous Cell Carcinoma of Head and Neck in search

Uterine Cervical Neoplasms2 of 3 · compare here

Pfizer in Uterine Cervical Neoplasms: 2 programs

  1. tucatinibapproved, new study
  2. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Uterine Cervical Neoplasms in search

–
Adenocarcinoma2 of 3 · compare here–

Hoffmann-La Roche in Adenocarcinoma: 1 program

  1. autogene cevumeranphase 2

Their studies: Hoffmann-La Roche’s studies of Adenocarcinoma in search

Merck in Adenocarcinoma: 1 program

  1. Medroxyprogesterone Acetatephase 2

Their studies: Merck’s studies of Adenocarcinoma in search

Anemia, Sickle Cell2 of 3 · compare here

Pfizer in Anemia, Sickle Cell: 1 program

  1. osivelotorphase 3

Their studies: Pfizer’s studies of Anemia, Sickle Cell in search

Hoffmann-La Roche in Anemia, Sickle Cell: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Anemia, Sickle Cell in search

–
Bacterial Infections2 of 3 · compare here–

Hoffmann-La Roche in Bacterial Infections: 1 program

  1. zosurabalpinphase 1

Their studies: Hoffmann-La Roche’s studies of Bacterial Infections in search

Merck in Bacterial Infections: 1 program

  1. tedizolid phosphatephase 3

Their studies: Merck’s studies of Bacterial Infections in search

Coronary Artery Disease2 of 3 · compare here–

Hoffmann-La Roche in Coronary Artery Disease: 1 program

  1. RO7763505phase 1

Their studies: Hoffmann-La Roche’s studies of Coronary Artery Disease in search

Merck in Coronary Artery Disease: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Coronary Artery Disease in search

Diabetic Retinopathy2 of 3 · compare here–

Hoffmann-La Roche in Diabetic Retinopathy: 1 program

  1. RO7663498phase 1

Their studies: Hoffmann-La Roche’s studies of Diabetic Retinopathy in search

Merck in Diabetic Retinopathy: 1 program

  1. MK-8748phase 3

Their studies: Merck’s studies of Diabetic Retinopathy in search

Esophageal Squamous Cell Carcinoma2 of 3 · compare here–

Hoffmann-La Roche in Esophageal Squamous Cell Carcinoma: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Esophageal Squamous Cell Carcinoma in search

Merck in Esophageal Squamous Cell Carcinoma: 1 program

  1. ifinatamab deruxtecanphase 3

Their studies: Merck’s studies of Esophageal Squamous Cell Carcinoma in search

Lymphoma, Follicular2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, Follicular: 1 program

  1. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Follicular in search

Merck in Lymphoma, Follicular: 1 program

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3

Their studies: Merck’s studies of Lymphoma, Follicular in search

Nasal Polyps2 of 3 · compare here

Pfizer in Nasal Polyps: 1 program

  1. rimegepantapproved, new study

Their studies: Pfizer’s studies of Nasal Polyps in search

Hoffmann-La Roche in Nasal Polyps: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Nasal Polyps in search

–
Non-alcoholic Fatty Liver Disease2 of 3 · compare here–

Hoffmann-La Roche in Non-alcoholic Fatty Liver Disease: 1 program

  1. pegozaferminphase 3

Their studies: Hoffmann-La Roche’s studies of Non-alcoholic Fatty Liver Disease in search

Merck in Non-alcoholic Fatty Liver Disease: 1 program

  1. efinopegdutidephase 2

Their studies: Merck’s studies of Non-alcoholic Fatty Liver Disease in search

Pneumonia2 of 3 · compare here

Pfizer in Pneumonia: 1 program

  1. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Pneumonia in search

–

Merck in Pneumonia: 1 program

  1. tedizolid phosphatephase 3

Their studies: Merck’s studies of Pneumonia in search

Psoriasis2 of 3 · compare here

Pfizer in Psoriasis: 1 program

  1. abrocitinibphase 3

Their studies: Pfizer’s studies of Psoriasis in search

–

Merck in Psoriasis: 1 program

  1. MK-8644phase 1

Their studies: Merck’s studies of Psoriasis in search

Vitiligo2 of 3 · compare here

Pfizer in Vitiligo: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Vitiligo in search

–

Merck in Vitiligo: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Vitiligo in search

Wet Macular Degeneration2 of 3 · compare here–

Hoffmann-La Roche in Wet Macular Degeneration: 1 program

  1. faricimabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Wet Macular Degeneration in search

Merck in Wet Macular Degeneration: 1 program

  1. MK-8748phase 3

Their studies: Merck’s studies of Wet Macular Degeneration in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Pfizer 67 of 91 · Hoffmann-La Roche 39 of 80 · Merck 40 of 84 programs (49 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9, Hoffmann-La Roche: 25).